Anavex Life Sciences Corp. AVXL
Regular-session close
After hours · Nov 20, 5:42 PM ET
- YTD
- -83.38%
- 1 year
- -81.34%
5D -0.3011 (-31.77%)
- Market cap
- 54.83M
- EPS (ttm)
- -0.14
- Shares out
- 84.80M
- Forward P/E
- -17.25
- YTD return
- -83.38%
- 1-year return
- -81.34%
- 50-day average
- 7.73
- 200-day average
- 5.65
- Enterprise value
- 593.03M
- Volume
- 1.64M
- Avg volume
- 1.13M
- Open
- 0.6675
- Previous close
- 0.6675
- Day's range
- 0.5901 – 0.71
- 52-week range
- 0.5901 – 5.36
- Beta
- 0.60
- Analysts
- Strong Buy
- Price target
- 35.47 (+5897.0%)
Key statistics
- Price / book
- 7.10
- Free cash flow
- -19.06M
- Total cash
- 138.76M
- Return on equity
- -30.03%
- Short % of float
- 23.96%
Fundamental scorecard
7 of 25 checks passed on AVXL’s reported financials
7of 25 checks passed
- Value 1 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 5 of 5
- Dividend 0 of 5
Statements to Jun 30, 2026.
Financials — quick view
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 23, 2024 | D. Boral Capital | main | Buy | Buy |
| Nov 27, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 26, 2024 | D. Boral Capital | main | Buy | Buy |
| Nov 25, 2024 | D. Boral Capital | main | Buy | Buy |
| Nov 4, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 31, 2024 | EF Hutton | main | Buy | Buy |
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- anavex.com
News
AVXL FINAL DEADLINE: ROSEN, A LONGSTANDING LAW FIRM, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important November 30 Deadline in Securities Class Action First Filed by the Firm - AVXL
What Does Anavex Life Sciences Corp.'s 6.35% Stock Drop Mean for Investors? The Law Offices of Howard G.
Kaplan Fox Alerts Anavex Life Sciences Corp. (AVXL) Investors to a Securities Fraud Lawsuit - Lead Plaintiff Deadline is November 30, 2026
AVXL DEADLINE FOR INVESTORS: Anavex Life Sciences Corp. Shareholders Encouraged to Contact Kirby McInerney LLP By November 30, 2026
ANAVEX DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important November 30 Deadline in Securities Class Action First Filed by the Firm - AVXL
What Should Anavex Life Sciences Corp. Investors Know After 6.35% Stock Drop? The Law Offices of Frank R.
SHAREHOLDER ALERT: Bronstein Gewirtz & Grossman, LLC Announces Class Action Against Anavex Life Sciences Corp. (NASDAQ: AVXL) — Investors Who Suffered Losses Are Encouraged to Contact the Firm
Faruqi & Faruqi, LLP Urges Anavex Life Sciences Corp. (AVXL) Investors to Seek Counsel Before the November 30, 2026 Lead Plaintiff Deadline in the Securities Class Action
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Anavex Life Sciences Corp. of Class Action Lawsuit and Upcoming Deadlines - AVXL
AVXL INVESTOR DEADLINE ALERT: Anavex Life Sciences Corp. Investors Seeking Lead Plaintiff Role Have Until November 30th to Contact Bragar Eagel & Squire, P.C.
Your note
Sign in to keep a note on AVXL — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DONHAUSER PETER D.O. | Director | Purchase | Jun 13, 2024 | 5,000 |
| MISSLING CHRISTOPHER U | Chief Executive Officer | Sale | Mar 27, 2024 | 1,250,210 |
| THOMAS STEFFEN PHD | Director | Purchase | May 14, 2024 | 5,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 7.95% | 6,740,696 | 73.27M | Sep 29, 2024 |
| Vanguard Group Inc | 5.59% | 4,740,171 | 51.53M | Sep 29, 2024 |
| State Street Corporation | 3.62% | 3,065,947 | 33.33M | Sep 29, 2024 |
| Geode Capital Management, LLC | 2.22% | 1,883,199 | 20.47M | Sep 29, 2024 |
| NWAM LLC | 1.07% | 910,476 | 9.90M | Sep 29, 2024 |
| Two Sigma Investments, LP | 0.98% | 830,624 | 9.03M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.99% | 2,534,500 | 27.55M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.30% | 1,946,169 | 21.15M | Oct 30, 2024 |
| SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 1.89% | 1,604,415 | 17.44M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.57% | 1,331,918 | 14.48M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.88% | 746,316 | 8.11M | Aug 30, 2024 |
| iShares Biotechnology ETF | 0.69% | 581,949 | 6.33M | Oct 30, 2024 |
